Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Chris Polman

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Concepts & Ideas

Anatomy

Physiology

Disease Progression

Chemicals & Drugs

Procedures

Phenomena

Recurrence

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Moraal Bastiaan; Pohl Christoph; Uitdehaag Bernard M J; Polman Chris H; Edan Gilles; Freedman Mark S; Hartung Hans-Peter; Kappos Ludwig; Miller David H; Montalban Xavier; Lanius Vivian; Sandbrink Rupert; Barkhof Frederik
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
Kappos Ludwig; Freedman Mark S; Polman Chris H; Edan Gilles; Hartung Hans-Peter; Miller David H; Montalbán Xavier; Barkhof Frederik; Radü Ernst-Wilhelm; Metzig Carola; Bauer Lars; Lanius Vivian; Sandbrink Rupert; Pohl Christoph;
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Eikelenboom M J; Killestein J; Kragt J J; Uitdehaag B M J; Polman C H
Gender differences in multiple sclerosis: cytokines and vitamin D.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Chris Polman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Moraal Bastiaan; Pohl Christoph; Uitdehaag Bernard M J; Polman Chris H; Edan Gilles; Freedman Mark S; Hartung Hans-Peter; Kappos Ludwig; Miller David H; Montalban Xavier; Lanius Vivian; Sandbrink Rupert; Barkhof Frederik
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
Archives of neurology 2009;66(11):1345-52.
2009: Kappos Ludwig; Freedman Mark S; Polman Chris H; Edan Gilles; Hartung Hans-Peter; Miller David H; Montalbán Xavier; Barkhof Frederik; Radü Ernst-Wilhelm; Metzig Carola; Bauer Lars; Lanius Vivian; Sandbrink Rupert; Pohl Christoph;
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Lancet neurology 2009;8(11):987-97.
2009: Eikelenboom M J; Killestein J; Kragt J J; Uitdehaag B M J; Polman C H
Gender differences in multiple sclerosis: cytokines and vitamin D.
Journal of the neurological sciences 2009;286(1-2):40-2.
2009: de Groot Vincent; Beckerman Heleen; Uitdehaag Bernard M; Hintzen Rogier Q; Minneboo Arjan; Heymans Martijn W; Lankhorst Gustaaf J; Polman Chris H; Bouter Lex M;
Physical and cognitive functioning after 3 years can be predicted using information from the diagnostic process in recently diagnosed multiple sclerosis.
Archives of physical medicine and rehabilitation 2009;90(9):1478-88.
2009: van der Voort L F; Visser A; Knol D L; Oudejans C B M; Polman C H; Killestein J
Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2009;16(9):1049-52.
2009: Korteweg T; Tintore M; Uitdehaag B M J; Knol D L; Vrenken H; Rovira A; Frederiksen J; Miller D H; Fernando K; Filippi M; Agosta F; Rocca M A; Fazekas F; Enzinger C; Parry A; Polman C H; Montalban X; Barkhof F
A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome.
European radiology 2009;19(9):2244-8.
2009: Rudick R A; Polman C H; Cohen J A; Walton M K; Miller A E; Confavreux C; Lublin F D; Hutchinson M; O'Connor P W; Schwid S R; Balcer L J; Lynn F; Panzara M A; Sandrock A W
Assessing disability progression with the Multiple Sclerosis Functional Composite.
Multiple sclerosis (Houndmills, Basingstoke, England) 2009;15(8):984-97.
2009: Labrijn Aran F; Buijsse Antonio Ortiz; van den Bremer Ewald T J; Verwilligen Annemiek Y W; Bleeker Wim K; Thorpe Susan J; Killestein Joep; Polman Chris H; Aalberse Rob C; Schuurman Janine; van de Winkel Jan G J; Parren Paul W H I
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.
Nature biotechnology 2009;27(8):767-71.
2009: Rudick Richard A; Polman Chris H
Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.
Lancet neurology 2009;8(6):545-59.
2009: van Winsen Lisa M L; Manenschijn Laura; van Rossum Elisabeth F C; Crusius J Bart A; Koper Jan Willem; Polman Chris H; Uitdehaag Bernard M J
A glucocorticoid receptor gene haplotype (TthIII1/ER22/23EK/9beta) is associated with a more aggressive disease course in multiple sclerosis.
The Journal of clinical endocrinology and metabolism 2009;94(6):2110-4.
2009: Baranzini Sergio E; Galwey Nicholas W; Wang Joanne; Khankhanian Pouya; Lindberg Raija; Pelletier Daniel; Wu Wen; Uitdehaag Bernard M J; Kappos Ludwig; Polman Chris H; Matthews Paul M; Hauser Stephen L; Gibson Rachel A; Oksenberg Jorge R; Barnes Michael R
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Human molecular genetics 2009;18(11):2078-90.
2009: Rovaris M; Barkhof F; Calabrese M; De Stefano N; Fazekas F; Miller D H; Montalban X; Polman C; Rocca M A; Thompson A J; Yousry T A; Filippi M
MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.
Neurology 2009;72(19):1693-701.
2009: Seewann Alexandra; Vrenken Hugo; van der Valk Paul; Blezer Erwin L A; Knol Dirk L; Castelijns Jonas A; Polman C H; Pouwels Petra J W; Barkhof Frederik; Geurts Jeroen J G
Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis.
Archives of neurology 2009;66(5):601-9.
2009: Vellinga Machteld M; Vrenken Hugo; Hulst Hanneke E; Polman Chris H; Uitdehaag Bernard M J; Pouwels Petra J W; Barkhof Frederik; Geurts Jeroen J G
Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study.
Journal of magnetic resonance imaging : JMRI 2009;29(4):774-9.
2009: Korteweg T; Rovaris M; Neacsu V; Filippi M; Comi G; Uitdehaag B M; Knol D L; Polman C H; Barkhof F; Vrenken H;
Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?
Multiple sclerosis (Houndmills, Basingstoke, England) 2009;15(4):465-71.
2009: Tenser Richard B; Polman Chris H
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.
Neurology 2009;72(13):1191-2; author reply 1192.
2009: Hutchinson Michael; Kappos Ludwig; Calabresi Peter A; Confavreux Christian; Giovannoni Gavin; Galetta Steven L; Havrdova Eva; Lublin Fred D; Miller David H; O'Connor Paul W; Phillips J Theodore; Polman Chris H; Radue Ernst-Wilhelm; Rudick Richard A; Stuart William H; Wajgt Andrzej; Weinstock-Guttman Bianca; Wynn Daniel R; Lynn Frances; Panzara Michael A;
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Journal of neurology 2009;256(3):405-15.
2009: Havrdova Eva; Galetta Steven; Hutchinson Michael; Stefoski Dusan; Bates David; Polman Chris H; O'Connor Paul W; Giovannoni Gavin; Phillips J Theodore; Lublin Fred D; Pace Amy; Kim Richard; Hyde Robert
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
Lancet neurology 2009;8(3):254-60.
2009: van der Voort L F; Kok A; Visser A; Oudejans C B M; Caldano M; Gilli F; Bertolotto A; Polman C H; Killestein J
Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
Multiple sclerosis (Houndmills, Basingstoke, England) 2009;15(2):212-8.
2009: Killestein Joep; Polman Chris H
[Alemtuzumab in early multiple sclerosis]
Nederlands tijdschrift voor geneeskunde 2009;153(1-2):46.
2009: Nielsen Jessica M; Pohl Christoph; Polman Chris H; Barkhof Frederik; Freedman Mark S; Edan Gilles; Miller David H; Bauer Lars; Sandbrink Rupert; Kappos Ludwig; Uitdehaag Bernard M J
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.
BMC neurology 2009;9():19.
2009: van der Linden Femke A H; Kragt Jolijn J; Hobart Jeremy C; Klein Martin; Thompson Alan J; van der Ploeg Henk M; Polman Chris H; Uitdehaag Bernard M J
The size of the treatment effect: do patients and proxies agree?
BMC neurology 2009;9():12.
2008: Teunissen C E; Killestein J; Kragt J J; Polman C H; Dijkstra C D; Blom H J
Serum homocysteine levels in relation to clinical progression in multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2008;79(12):1349-53.
2008: Kappos Ludwig; Gold Ralf; Miller David H; Macmanus David G; Havrdova Eva; Limmroth Volker; Polman Chris H; Schmierer Klaus; Yousry Tarek A; Yang Minhua; Eraksoy Mefkûre; Meluzinova Eva; Rektor Ivan; Dawson Katherine T; Sandrock Alfred W; O'Neill Gilmore N;
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Lancet 2008;372(9648):1463-72.
2008: van der Linden F A H; D'hooghe M B; Nagels G; Van Nunen A; Polman C H; Uitdehaag B M J
Proxy ratings from multiple sources: disagreement on the impact of multiple sclerosis on daily life.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2008;15(9):933-9.
2008: Minneboo A; Jasperse B; Barkhof F; Uitdehaag B M J; Knol D L; de Groot V; Polman C H; Castelijns J A
Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters.
Journal of neurology, neurosurgery, and psychiatry 2008;79(8):917-23.
2008: Rocca Maria A; Agosta Federica; Sormani Maria P; Fernando Kryshani; Tintorè Mar; Korteweg Tijmen; Tortorella Paola; Miller David H; Thompson Alan; Rovira Alex; Montalban Xavier; Polman Chris; Barkhof Frederik; Filippi Massimo
A three-year, multi-parametric MRI study in patients at presentation with CIS.
Journal of neurology 2008;255(5):683-91.
2008: Zwemmer J N P; Bot J C J; Jelles B; Barkhof F; Polman C H
At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only.
Multiple sclerosis (Houndmills, Basingstoke, England) 2008;14(3):428-30.
2008: Polman C H; Reingold S C; Barkhof F; Calabresi P A; Clanet M; Cohen J A; Cutter G R; Freedman M S; Kappos L; Lublin F D; McFarland H F; Metz L M; Miller A E; Montalban X; O'Connor P W; Panitch H; Richert J R; Petkau J; Schwid S R; Sormani M P; Thompson A J; Weinshenker B G; Wolinsky J S
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.
Neurology 2008;70(13 Pt 2):1134-40.
2008: Vellinga Machteld M; Oude Engberink Raoul D; Seewann Alexandra; Pouwels Petra J W; Wattjes Mike P; van der Pol Susanne M A; Pering Christiane; Polman Chris H; de Vries Helga E; Geurts Jeroen J G; Barkhof Frederik
Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement.
Brain : a journal of neurology 2008;131(Pt 3):800-7.
2008: Kragt J J; Thompson A J; Montalban X; Tintoré M; Río J; Polman C H; Uitdehaag B M J
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Neurology 2008;70(13 Pt 2):1084-91.
2008: Vellinga M M; Castelijns J A; Barkhof F; Uitdehaag B M J; Polman C H
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.
Neurology 2008;70(13 Pt 2):1150-1.
2008: de Groot Vincent; Beckerman Heleen; Twisk Jos W; Uitdehaag Bernard M; Hintzen Rogier Q; Minneboo Arjan; Lankhorst Gustaaf J; Polman Chris H; Bouter Lex M
Vitality, perceived social support and disease activity determine the performance of social roles in recently diagnosed multiple sclerosis: a longitudinal analysis.
Journal of rehabilitation medicine : official journal of the UEMS European Board of Physical and Rehabilitation Medicine 2008;40(2):151-7.
2008: Geurts Jeroen J G; Blezer Erwin L A; Vrenken Hugo; van der Toorn Annette; Castelijns Jonas A; Polman Chris H; Pouwels Petra J W; Bö Lars; Barkhof Frederik
Does high-field MR imaging improve cortical lesion detection in multiple sclerosis?
Journal of neurology 2008;255(2):183-91.
2008: Wegner C; Filippi M; Korteweg T; Beckmann C; Ciccarelli O; De Stefano N; Enzinger C; Fazekas F; Agosta F; Gass A; Hirsch J; Johansen-Berg H; Kappos L; Barkhof F; Polman C; Mancini L; Manfredonia F; Marino S; Miller D H; Montalban X; Palace J; Rocca M; Ropele S; Rovira A; Smith S; Thompson A; Thornton J; Yousry T; Matthews P M
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2008;15(2):113-22.
2008: Polman Chris H
Early diagnosis of multiple sclerosis-still a challenge?
Multiple sclerosis (Houndmills, Basingstoke, England) 2008;14(1):2-3.
2008: van Baarsen Lisa G M; Vosslamber Saskia; Tijssen Marianne; Baggen Josefien M C; van der Voort Laura F; Killestein Joep; van der Pouw Kraan Tineke C T M; Polman Chris H; Verweij Cornelis L
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
PloS one 2008;3(4):e1927.
2008: van der Linden Femke A H; Kragt Jolijn J; van Bon Margarethe; Klein Martin; Thompson Alan J; van der Ploeg Henk M; Polman Chris H; Uitdehaag Bernard M J
Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years.
BMC neurology 2008;8():2.
2007: Jasperse Bas; Vrenken Hugo; Sanz-Arigita Ernesto; de Groot Vincent; Smith Stephen M; Polman Chris H; Barkhof Frederik
Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis.
NeuroImage 2007;38(3):529-37.
2007: Polman C H; Deisenhammer F; Giovannoni G; Killestein J; Schellekens H
Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Neurology 2007;69(15):1553-4; author reply 1555.
2007: Jasperse Bas; Valsasina Paola; Neacsu Veronica; Knol Dirk L; De Stefano Nicola; Enzinger Christian; Smith Stephen M; Ropele Stefan; Korteweg Tijmen; Giorgio Antonio; Anderson Valerie; Polman Chris H; Filippi Massimo; Miller David H; Rovaris Marco; Barkhof Frederik; Vrenken Hugo;
Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX.
Journal of magnetic resonance imaging : JMRI 2007;26(4):881-5.
2007: van Veen Tineke; Nielsen Jessica; Berkhof Johannes; Barkhof Frederik; Kamphorst Wouter; Bö Lars; Ravid Rivka; Verweij Cor L; Huitinga Inge; Polman Chris H; Uitdehaag Bernard M J
CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis.
Journal of neuroimmunology 2007;190(1-2):157-64.
2007: Liedorp M; Sanchez E; van Hoogstraten I M W; von Blomberg B M E; Barkhof F; Polman C H; Killestein J
No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up.
Journal of neurology, neurosurgery, and psychiatry 2007;78(10):1146-8.
2007: Calabresi P A; Giovannoni G; Confavreux C; Galetta S L; Havrdova E; Hutchinson M; Kappos L; Miller D H; O'Connor P W; Phillips J T; Polman C H; Radue E-W; Rudick R A; Stuart W H; Lublin F D; Wajgt A; Weinstock-Guttman B; Wynn D R; Lynn F; Panzara M A;
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Neurology 2007;69(14):1391-403.
2007: Rudick Richard A; Miller Deborah; Hass Steve; Hutchinson Michael; Calabresi Peter A; Confavreux Christian; Galetta Steven L; Giovannoni Gavin; Havrdova Eva; Kappos Ludwig; Lublin Fred D; Miller David H; O'Connor Paul W; Phillips J Theodore; Polman Chris H; Radue Ernst-Wilhelm; Stuart William H; Wajgt Andrzej; Weinstock-Guttman Bianca; Wynn Daniel R; Lynn Frances; Panzara Michael A;
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Annals of neurology 2007;62(4):335-46.
2007: Barkhof Frederik; Polman Chris H; Radue Ernst-Wilhelm; Kappos Ludwig; Freedman Mark S; Edan Gilles; Hartung Hans-Peter; Miller David H; Montalbán Xavier; Poppe Peter; de Vos Marlieke; Lasri Fatiha; Bauer Lars; Dahms Susanne; Wagner Klaus; Pohl Christoph; Sandbrink Rupert
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
Archives of neurology 2007;64(9):1292-8.
2007: Kappos Ludwig; Freedman Mark S; Polman Chris H; Edan Gilles; Hartung Hans-Peter; Miller David H; Montalbán Xavier; Barkhof Frederik; Radü Ernst-Wilhelm; Bauer Lars; Dahms Susanne; Lanius Vivian; Pohl Christoph; Sandbrink Rupert;
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
Lancet 2007;370(9585):389-97.
2007: Swanton Josephine K; Rovira Alex; Tintore Mar; Altmann Daniel R; Barkhof Frederik; Filippi Massimo; Huerga Elena; Miszkiel Katherine A; Plant Gordon T; Polman Chris; Rovaris Marco; Thompson Alan J; Montalban Xavier; Miller David H
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study.
Lancet neurology 2007;6(8):677-86.
2007: Nielsen J M; Moraal B; Polman C H; Poppe P; de Vos M; Freedman M S; Kappos L; Barkhof F; Bauer L; Pohl C; Sandbrink R; Hartung H-P; Uitdehaag B M J
Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results.
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(6):717-21.
2007: Vrenken H; Pouwels P J W; Ropele S; Knol D L; Geurts J J G; Polman C H; Barkhof F; Castelijns J A
Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease.
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(6):708-16.
2007: Hartung Hans-P; Polman Chris; Bertolotto Antonio; Deisenhammer Florian; Giovannoni Gavin; Havrdova Eva; Hemmer Bernhard; Hillert Jan; Kappos Ludwig; Kieseier Bernd; Killestein Joep; Malcus Christophe; Comabella Manuel; Pachner Andrew; Schellekens Huub; Sellebjerg Finn; Selmaj Krysztof; Sorensen Per Soelberg
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
Journal of neurology 2007;254(7):827-37.
2007: Uitdehaag B M J; Jelles B; Killestein J; van Oosten B W; Polman C H
[Immunomodulatory therapy in multiple sclerosis]
Nederlands tijdschrift voor geneeskunde 2007;151(25):1435; author reply 1435-6.
2007: Kalkers N F; Strijers R L M; Jasperse M M S; Neacsu V; Geurts J J G; Barkhof F; Polman C H; Stam C J
Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2007;118(6):1332-40.
2007: Kappos Ludwig; Bates David; Hartung Hans-Peter; Havrdova Eva; Miller David; Polman Chris H; Ravnborg Mads; Hauser Stephen L; Rudick Richard A; Weiner Howard L; O'Connor Paul W; King John; Radue Ernst Wilhelm; Yousry Tarek; Major Eugene O; Clifford David B
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
Lancet neurology 2007;6(5):431-41.
2007: Jasperse Bas; Jakobs Cornelis; Eikelenboom M Judith; Dijkstra Christine D; Uitdehaag Bernard M J; Barkhof Frederik; Polman Chris H; Teunissen Charlotte E
N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry.
Journal of neurology 2007;254(5):631-7.
2007: van Winsen L M L; Hooper-van Veen T; van Rossum E F C; Koper J W; Barkhof F; Polman C H; Uitdehaag B M J
Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS.
Journal of neuroimmunology 2007;186(1-2):150-5.
2007: Miller D H; Soon D; Fernando K T; MacManus D G; Barker G J; Yousry T A; Fisher E; O'Connor P W; Phillips J T; Polman C H; Kappos L; Hutchinson M; Havrdova E; Lublin F D; Giovannoni G; Wajgt A; Rudick R; Lynn F; Panzara M A; Sandrock A W;
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Neurology 2007;68(17):1390-401.
2007: Balcer L J; Galetta S L; Calabresi P A; Confavreux C; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; Lublin F D; Miller D H; O'Connor P W; Phillips J T; Polman C H; Radue E-W; Rudick R A; Stuart W H; Wajgt A; Weinstock-Guttman B; Wynn D R; Lynn F; Panzara M A
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
Neurology 2007;68(16):1299-304.
2007: Nielsen J M; Korteweg T; Polman C H
Diagnosing MS: recent guidelines and future goals focusing on magnetic resonance imaging.
International MS journal / MS Forum 2007;14(1):29-34.
2007: Soon Derek; Altmann Daniel R; Fernando Kryshani T M; Giovannoni Garin; Barkhof Frederick; Polman Chris H; O'Connor Paul; Gray Bruce; Panzara Michael; Miller David H
A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.
Journal of neurology 2007;254(3):306-14.
2007: Jasperse Bas; Minneboo Arjan; de Groot Vincent; Kalkers Nynke F; van Helden Paul E; Uitdehaag Bernard M J; Barkhof Frederik; Polman Chris H
Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis.
Archives of neurology 2007;64(2):190-4.
2007: Kuhle Jens; Pohl Christoph; Mehling Matthias; Edan Gilles; Freedman Mark S; Hartung Hans-Peter; Polman Chris H; Miller David H; Montalban Xavier; Barkhof Frederik; Bauer Lars; Dahms Susanne; Lindberg Raija; Kappos Ludwig; Sandbrink Rupert
Lack of association between antimyelin antibodies and progression to multiple sclerosis.
The New England journal of medicine 2007;356(4):371-8.
2007: Bö Lars; Geurts Jeroen J G; van der Valk Paul; Polman Chris; Barkhof Frederik
Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis.
Archives of neurology 2007;64(1):76-80.
2007: Korteweg Tijmen; Uitdehaag Bernard M J; Knol Dirk L; Smithuis Robin H M; Algra Paul R; de Vries Cees; Poppe Peter A; van Waesberghe Jan-Hein T M; Bergers Elisabeth; Lycklama à Nijeholt Geert J; Polman Chris H; Barkhof Frederik
Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis.
European radiology 2007;17(1):67-71.
2006: Kragt J J; Nielsen I M; van der Linden F A H; Uitdehaag B M J; Polman C H
How similar are commonly combined criteria for EDSS progression in multiple sclerosis?
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(6):782-6.
2006: Lazeron R H C; de Sonneville L M J; Scheltens P; Polman C H; Barkhof F
Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(6):760-8.
2006: Lopatinskaya L; Zwemmer J; Uitdehaag B; Lucas K; Polman C; Nagelkerken L
Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(6):704-9.
2006: Phillips J T; O'Connor P W; Havrdova E; Hutchinson M; Kappos L; Miller D H; Polman C H; Lublin F D; Giovannoni G; Wajgt A; Lynn F; Panzara M A; Sandrock A W;
Infusion-related hypersensitivity reactions during natalizumab treatment.
Neurology 2006;67(9):1717-8.
2006: Kragt J J; van der Linden F A H; Nielsen J M; Uitdehaag B M J; Polman C H
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(5):594-8.
2006: Zwemmer J N P; Berkhof J; Castelijns J A; Barkhof F; Polman C H; Uitdehaag B M J
Classification of multiple sclerosis patients by latent class analysis of magnetic resonance imaging characteristics.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(5):565-72.
2006: Vrenken H; Geurts J J G; Knol D L; Polman C H; Castelijns J A; Pouwels P J W; Barkhof F
Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis.
AJNR. American journal of neuroradiology 2006;27(9):2005-11.
2006: Charil Arnaud; Yousry Tarek A; Rovaris Marco; Barkhof Frederik; De Stefano Nicola; Fazekas Franz; Miller David H; Montalban Xavier; Simon Jack H; Polman Chris; Filippi Massimo
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation".
Lancet neurology 2006;5(10):841-52.
2006: de Groot V; Beckerman H; Uitdehaag B M J; de Vet H C W; Lankhorst G J; Polman C H; Bouter L M
The usefulness of evaluative outcome measures in patients with multiple sclerosis.
Brain : a journal of neurology 2006;129(Pt 10):2648-59.
2006: Kappos L; Polman C H; Freedman M S; Edan G; Hartung H P; Miller D H; Montalban X; Barkhof F; Bauer L; Jakobs P; Pohl C; Sandbrink R
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Neurology 2006;67(7):1242-9.
2006: van der Linden F A H; Kragt J J; Hobart J C; Klein M; Thompson A J; van der Ploeg H M; Polman C H; Uitdehaag B M J
Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life.
Journal of neurology, neurosurgery, and psychiatry 2006;77(10):1157-62.
2006: Kobelt Gisela; Berg J; Lindgren P; Anten Bert; Ekman Mattias; Jongen Peter J H; Polman Chris; Uitdehaag Bernard
Costs and quality of life in multiple sclerosis in The Netherlands.
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S55-64.
2006: Kappos Ludwig; Antel Jack; Comi Giancarlo; Montalban Xavier; O'Connor Paul; Polman Chris H; Haas Tomas; Korn Alexander A; Karlsson Goeril; Radue Ernst W;
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
The New England journal of medicine 2006;355(11):1124-40.
2006: Vrenken Hugo; Geurts Jeroen J G; Knol Dirk L; van Dijk L Noor; Dattola Vincenzo; Jasperse Bas; van Schijndel Ronald A; Polman Chris H; Castelijns Jonas A; Barkhof Frederik; Pouwels Petra J W
Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter.
Radiology 2006;240(3):811-20.
2006: van Baarsen L G M; van der Pouw Kraan T C T M; Kragt J J; Baggen J M C; Rustenburg F; Hooper T; Meilof J F; Fero M J; Dijkstra C D; Polman C H; Verweij C L
A subtype of multiple sclerosis defined by an activated immune defense program.
Genes and immunity 2006;7(6):522-31.
2006: Breij Esther C W; Heijnen Priscilla; van der Goes Annette; Teunissen Charlotte E; Polman Chris H; Dijkstra Christine D
Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients.
Journal of neuroimmunology 2006;176(1-2):106-14.
2006: Petzold A; Eikelenboom M I; Keir G; Polman C H; Uitdehaag B M J; Thompson E J; Giovannoni G
The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(3):325-8.
2006: van Noort J M; Verbeek R; Meilof J F; Polman C H; Amor S
Autoantibodies against alpha B-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(3):287-93.
2006: Polman Chris; Schellekens Huub; Killestein Joep
Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(3):245-6.
2006: Huijbregts Stephan C J; Kalkers Nynke F; de Sonneville Leo M J; de Groot Vincent; Polman Chris H
Cognitive impairment and decline in different MS subtypes.
Journal of the neurological sciences 2006;245(1-2):187-94.
2006: Teunissen C E; Dijkstra C D; Jasperse B; Barkhof F; Vanderstichele H; Vanmechelen E; Polman C H; Bö L
Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis.
Neuropathology and applied neurobiology 2006;32(3):318-31.
2006: Hooper-van Veen Tineke; Berkhof Johannes; Polman Chris H; Uitdehaag Bernard M J
Analysing the effect of candidate genes on complex traits: an application in multiple sclerosis.
Immunogenetics 2006;58(5-6):347-54.
2006: Nielsen Jessica M; Barkhof Frederik; van Oosten Bob W; Polman Chris H
The role of spinal cord imaging in the diagnosis of multiple sclerosis.
Nature clinical practice. Neurology 2006;2(5):283-6; quiz 287.
2006: Polman Chris H; Reingold Stephen C; Weinshenker Brian G
Reply.
Annals of neurology 2006;59(5):871.
2006: Vrenken Hugo; Pouwels Petra J W; Geurts Jeroen J G; Knol Dirk L; Polman Chris H; Barkhof Frederik; Castelijns Jonas A
Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration.
Journal of magnetic resonance imaging : JMRI 2006;23(5):628-36.
2006: Polman Chris H; O'Connor Paul W; Havrdova Eva; Hutchinson Michael; Kappos Ludwig; Miller David H; Phillips J Theodore; Lublin Fred D; Giovannoni Gavin; Wajgt Andrzej; Toal Martin; Lynn Frances; Panzara Michael A; Sandrock Alfred W;
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
The New England journal of medicine 2006;354(9):899-910.
2006: Korteweg Tijmen; Tintoré Mar; Uitdehaag Bernard; Rovira Alex; Frederiksen Jette; Miller David; Fernando Kryshani; Filippi Massimo; Agosta Federica; Rocca Maria; Fazekas Franz; Enzinger Christian; Matthews Paul; Parry Allyson; Polman Chris; Montalban Xavier; Barkhof Frederik
MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study.
Lancet neurology 2006;5(3):221-7.
2006: Geurts Jeroen J G; Reuling Ilona E W; Vrenken Hugo; Uitdehaag Bernard M J; Polman Chris H; Castelijns Jonas A; Barkhof Frederik; Pouwels Petra J W
MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2006;55(3):478-83.
2006: Cover Keith S; Vrenken Hugo; Geurts Jeroen J G; van Oosten Bob W; Jelles Brechtje; Polman Chris H; Stam Cornelis J; van Dijk Bob W
Multiple sclerosis patients show a highly significant decrease in alpha band interhemispheric synchronization measured using MEG.
NeuroImage 2006;29(3):783-8.
2005: de Groot V; Beckerman H; Lankhorst G J; Polman C H; Bouter L M
The initial course of daily functioning in multiple sclerosis: a three-year follow-up study.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(6):713-8.
2005: van der Linden F A H; Kragt J J; Klein M; van der Ploeg H M; Polman C H; Uitdehaag B M J
Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use.
Journal of neurology, neurosurgery, and psychiatry 2005;76(12):1677-81.
2005: Polman Chris H; Reingold Stephen C; Edan Gilles; Filippi Massimo; Hartung Hans-Peter; Kappos Ludwig; Lublin Fred D; Metz Luanne M; McFarland Henry F; O'Connor Paul W; Sandberg-Wollheim Magnhild; Thompson Alan J; Weinshenker Brian G; Wolinsky Jerry S
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Annals of neurology 2005;58(6):840-6.
2005: Camp S J; Stevenson V L; Thompson A J; Ingle G T; Miller D H; Borras C; Brochet B; Dousset V; Falautano M; Filippi M; Kalkers N F; Montalban X; Polman C H; Langdon D W
A longitudinal study of cognition in primary progressive multiple sclerosis.
Brain : a journal of neurology 2005;128(Pt 12):2891-8.
2005: Sormani Maria Pia; Bruzzi Paolo; Beckmann Karola; Kappos Ludwig; Miller David H; Polman Chris; Pozzilli Carlo; Thompson Alan J; Wagner Klaus; Filippi Massimo
The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis.
Journal of neurology 2005;252(12):1455-8.
2005: Nielsen Jessica M; Korteweg Tijmen; Barkhof Frederik; Uitdehaag Bernard M J; Polman Chris H
Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria.
Annals of neurology 2005;58(5):781-3.
2005: Lazeron R H C; Boringa J B; Schouten M; Uitdehaag B M J; Bergers E; Lindeboom J; Eikelenboom M I; Scheltens P H; Barkhof F; Polman C H
Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(5):524-31.
2005: Eikelenboom M J; Killestein J; Uitdehaag B M J; Polman C H
Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(5):520-3.
2005: van Winsen Lisa L M; Hooper-van Veen Tineke; van Rossum Elisabeth F C; Polman Chris H; van den Berg Timo K; Koper Jan W; Uitdehaag Bernard M J
The impact of glucocorticoid receptor gene polymorphisms on glucocorticoid sensitivity is outweighted in patients with multiple sclerosis.
Journal of neuroimmunology 2005;167(1-2):150-6.
2005: Sastre-Garriga J; Ingle G T; Rovaris M; Téllez N; Jasperse B; Altmann D R; Benedetti B; Stevenson V L; Cercignani M; Leary S M; Barkhof F; Brochet B; Dousset V; Filippi M; Montalban X; Kalkers N F; Polman C H; Rovira A; Miller D H; Thompson A J
Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data.
Neurology 2005;65(4):633-5.
2005: Minneboo A; Uitdehaag B M J; Ader H J; Barkhof F; Polman C H; Castelijns J A
Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients.
Neurology 2005;65(1):56-61.
2005: Geurts Jeroen J G; Pouwels Petra J W; Uitdehaag Bernard M J; Polman Chris H; Barkhof Frederik; Castelijns Jonas A
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging.
Radiology 2005;236(1):254-60.
2005: Killestein Joep; Kalkers Nynke F; Polman Chris H
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
Journal of the neurological sciences 2005;233(1-2):113-5.
2005: Killestein Joep; Polman Chris H
Current trials in multiple sclerosis: established evidence and future hopes.
Current opinion in neurology 2005;18(3):253-60.
2005: Rieckmann Peter; Kruse N; Nagelkerken L; Beckmann K; Miller D; Polman C; Dahlke F; Toyka K V; Hartung H P; Stürzebecher S
Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis.
Journal of neurology 2005;252(5):526-33.
2005: Uitdehaag Bernard M J; Kappos Ludwig; Bauer Lars; Freedman Mark S; Miller David; Sandbrink Rupert; Polman Chris H
Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(2):227-31.
2005: Korteweg Tijmen; Barkhof Frederik; Uitdehaag Bernard M J; Polman Chris H
How to use spinal cord magnetic resonance imaging in the McDonald diagnostic criteria for multiple sclerosis.
Annals of neurology 2005;57(4):606-7.
2005: Fabriek Babs O; Zwemmer Jack N P; Teunissen Charlotte E; Dijkstra Christine D; Polman Chris H; Laman Jon D; Castelijns Jonas A
In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology.
Journal of neuroimmunology 2005;161(1-2):190-4.
2005: Polman C H; Kappos L; Dahlke F; Graf R; Beckmann K; Bogumil T; Pozzilli C; Thompson A J;
Interferon beta-1b treatment does not induce autoantibodies.
Neurology 2005;64(6):996-1000.
2005: Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Neurology 2005;64(6):987-91.
2005: Geurts Jeroen J G; Bö Lars; Pouwels Petra J W; Castelijns Jonas A; Polman Chris H; Barkhof Frederik
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology.
AJNR. American journal of neuroradiology 2005;26(3):572-7.
2005: Polman Chris H; Wolinsky Jerry S; Reingold Stephen C
Multiple sclerosis diagnostic criteria: three years later.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(1):5-12.
2005: Vrenken H; Barkhof F; Uitdehaag B M J; Castelijns J A; Polman C H; Pouwels P J W
MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2005;53(2):256-66.
2005: Petzold A; Eikelenboom M J; Keir G; Grant D; Lazeron R H C; Polman C H; Uitdehaag B M J; Thompson E J; Giovannoni G
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.
Journal of neurology, neurosurgery, and psychiatry 2005;76(2):206-11.
2005: van Winsen Lisa M L; Muris Daan F R; Polman Chris H; Dijkstra Christine D; van den Berg Timo K; Uitdehaag Bernard M J
Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis.
The Journal of clinical endocrinology and metabolism 2005;90(2):734-40.
2005: Teunissen Charlotte E; Dijkstra Christine; Polman Chris
Biological markers in CSF and blood for axonal degeneration in multiple sclerosis.
Lancet neurology 2005;4(1):32-41.
2005: Eikelenboom M Judith; Killestein Joep; Izeboud Thijs; Kalkers Nynke F; Baars Paul A; van Lier Rene A W; Barkhof Frederik; Uitdehaag Bernard M J; Polman Chris H
Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.
Journal of neuroimmunology 2005;158(1-2):222-30.
2005: Teunissen Charlotte E; van Boxtel Martin P J; Jolles Jellemer; de Vente Jan; Vreeling Fred; Verhey Frans; Polman Chris H; Dijkstra Christine D; Blom Henk J
Homocysteine in relation to cognitive performance in pathological and non-pathological conditions.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2005;43(10):1089-95.
2005: Scherder Erik; Wolters Erik; Polman Chris; Sergeant Joseph; Swaab Dick
Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems.
Neuroscience and biobehavioral reviews 2005;29(7):1047-56.
2004: Visschedijk Mariëlle A J; Collette Emma H; Polman Chris H; Pfennings Lilian E M A; van der Ploeg Henk M
Development of a cognitive behavioral group intervention programme for patients with multiple sclerosis: an exploratory study.
Psychological reports 2004;95(3 Pt 1):735-46.
2004: Visschedijk M A J; Uitdehaag B M J; Klein M; van der Ploeg E; Collette E H; Vleugels L; Pfennings L E M A; Hoogervorst E L J; van der Ploeg H M; Polman C H
Value of health-related quality of life to predict disability course in multiple sclerosis.
Neurology 2004;63(11):2046-50.
2004: Killestein J; Bet P M; van Loenen A C; Polman C H
[Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness]
Nederlands tijdschrift voor geneeskunde 2004;148(48):2374-8.
2004: Kappos L; Weinshenker B; Pozzilli C; Thompson A J; Dahlke F; Beckmann K; Polman C; McFarland H;
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
Neurology 2004;63(10):1779-87.
2004: Kragt J Jolijn; Hoogervorst Erwin L J; Uitdehaag Bernard M J; Polman Chris H
Relation between objective and subjective measures of bladder dysfunction in multiple sclerosis.
Neurology 2004;63(9):1716-8.
2004: Bot Joseph C J; Blezer Erwin L A; Kamphorst Wouter; Lycklama A Nijeholt Geert J; Ader Herman J; Castelijns Jonas A; Ig Klaas Nicolay; Bergers Elisabeth; Ravid Rivka; Polman Chris; Barkhof Frederik
The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results.
Radiology 2004;233(2):531-40.
2004: Rejdak K; Eikelenboom M J; Petzold A; Thompson E J; Stelmasiak Z; Lazeron R H C; Barkhof F; Polman C H; Uitdehaag B M J; Giovannoni G
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.
Neurology 2004;63(8):1439-45.
2004: Hoogervorst E L J; Zwemmer J N P; Jelles B; Polman C H; Uitdehaag B M J
Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(5):569-74.
2004: Lazeron Richard H C; Rombouts Serge A R B; Scheltens Philip; Polman Chris H; Barkhof Frederik
An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(5):549-55.
2004: Vogt M H J; Floris S; Killestein J; Knol D L; Smits M; Barkhof F; Polman C H; Nagelkerken L
Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients.
Journal of neuroimmunology 2004;155(1-2):155-60.
2004: Schrijver Hans M; Crusius J Bart A; García-González M Asunçion; Polman Chris H; Peña A Salvador; Barkhof Frederik; Uitdehaag Bernard M J
Gender-related association between the TGFB1+869 polymorphism and multiple sclerosis.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2004;24(9):536-42.
2004: Geurts Jeroen J G; Barkhof Frederik; Castelijns Jonas A; Uitdehaag Bernard M J; Polman Chris H; Pouwels Petra J W
Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility.
Journal of magnetic resonance imaging : JMRI 2004;20(3):366-71.
2004: Killestein Joep; Polman Chris
The therapeutic value of cannabinoids in MS: real or imaginary?
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(4):339-40.
2004: Miller D H; Filippi M; Fazekas F; Frederiksen J L; Matthews P M; Montalban X; Polman C H
Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis.
Annals of neurology 2004;56(2):273-8.
2004: VanAmerongen B M; Dijkstra C D; Lips P; Polman C H
Multiple sclerosis and vitamin D: an update.
European journal of clinical nutrition 2004;58(8):1095-109.
2004: Huijbregts S C J; Kalkers N F; de Sonneville L M J; de Groot V; Reuling I E W; Polman C H
Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.
Neurology 2004;63(2):335-9.
2004: Eikelenboom M J; Killestein J; Uitdehaag B M; Polman C H
Opticospinal multiple sclerosis: a pathogenetically distinct form?
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(3):334-5.
2004: van Oosten B W; Killestein J; Mathus-Vliegen E M H; Polman C H
Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(3):330-1.
2004: Zwemmer J N P; van Veen T; van Winsen L; van Kamp G J; Barkhof F; Polman C H; Uitdehaag B M J
No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(3):272-7.
2004: Polman Chris H; Killestein Joep
Statins for the treatment of multiple sclerosis: cautious hope.
Lancet 2004;363(9421):1570.
2004: de Jonge Peter; Hoogervorst Erwin L J; Huyse Frits J; Polman Chris H
INTERMED: a measure of biopsychosocial case complexity: one year stability in Multiple Sclerosis patients.
General hospital psychiatry 2004;26(2):147-52.
2004: Floris Sarah; van der Goes Annette; Killestein Joep; Knol Dirk L; Barkhof Frederik; Polman Chris H; Dijkstra Christine D; de Vries Helga E; Meilof Jan F
Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels.
Journal of neuroimmunology 2004;148(1-2):172-7.
2004: Minneboo Arjan; Barkhof Frederick; Polman Chris H; Uitdehaag Bernard M J; Knol Dirk L; Castelijns Jonas A
Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis.
Archives of neurology 2004;61(2):217-21.
2004: Hoogervorst E L J; Kalkers N F; Cutter G R; Uitdehaag B M J; Polman C H
The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(1):55-60.
2004: Polman Chris H; Wolinsky Jerry S; Reingold Stephen C
Multiple sclerosis: should MR criteria for dissemination in time be less stringent.
Annals of neurology 2004;55(2):297.
2004: Bot J C J; Barkhof F; Polman C H; Lycklama à Nijeholt G J; de Groot V; Bergers E; Ader H J; Castelijns J A
Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination.
Neurology 2004;62(2):226-33.
2004: Killestein Joep; Uitdehaag Bernard M J; Polman Chris H
Cannabinoids in multiple sclerosis: do they have a therapeutic role?
Drugs 2004;64(1):1-11.
2003: Kappos L; Polman C; Thompson A J; Duda P; Clanet M; Comi G; Hartung H P; Montalban X
Towards a european network for multiple sclerosis trials (ENMST).
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(6):627-9.
2003: Hooper-van Veen Tineke; Schrijver Hans M; Zwiers Antoon; Crusius J Bart A; Knol Dirk L; Kalkers Nynke F; Laine Marja L; Barkhof Frederik; Peña A Salvador; Polman Chris H; Uitdehaag Bernard M J
The interleukin-1 gene family in multiple sclerosis susceptibility and disease course.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(6):535-9.
2003: van Walderveen Marianne A A; van Schijndel Ronald A; Pouwels Petra J W; Polman Chris H; Barkhof Frederik
Multislice T1 relaxation time measurements in the brain using IR-EPI: reproducibility, normal values, and histogram analysis in patients with multiple sclerosis.
Journal of magnetic resonance imaging : JMRI 2003;18(6):656-64.
2003: van Veen T; van Winsen L; Crusius J B A; Kalkers N F; Barkhof F; Peña A S; Polman C H; Uitdehaag B M J
[Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype.
Neurology 2003;61(9):1245-9.
2003: Killestein Joep; Eikelenboom M Judith; Izeboud Thijs; Kalkers Nynke F; Adèr Herman J; Barkhof Frederik; Van Lier Rene A W; Uitdehaag Bernard M J; Polman Chris H
Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.
Journal of neuroimmunology 2003;142(1-2):141-8.
2003: Polman Chris H; Jansen Paul H P; Jansen Cees; Uitdehaag Bernard M J
A rare, treatable cause of relapsing encephalopathy in an MS patient on interferon beta therapy.
Neurology 2003;61(5):719.
2003: Polman Chris H; Uitdehaag Bernard M J
New and emerging treatment options for multiple sclerosis.
Lancet neurology 2003;2(9):563-6.
2003: Lycklama Geert; Thompson Alan; Filippi Massimo; Miller David; Polman Chris; Fazekas Franz; Barkhof Frederik
Spinal-cord MRI in multiple sclerosis.
Lancet neurology 2003;2(9):555-62.
2003: Killestein Joep; Polman Chris H
Cannabis use in multiple sclerosis: excited interest.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2003;30(3):181-2.
2003: Polman C; Barkhof F; Kappos L; Pozzilli C; Sandbrink R; Dahlke F; Jakobs P; Lorenz A;
Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(4):342-8.
2003: Barkhof Frederik; Bruck Wolfgang; De Groot Corline J A; Bergers Elisabeth; Hulshof Sandra; Geurts Jeroen; Polman Chris H; van der Valk Paul
Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.
Archives of neurology 2003;60(8):1073-81.
2003: Killestein Joep; Uitdehaag Bernard M J; Polman Chris H
Cannabinoids and immune function.
JAMA : the journal of the American Medical Association 2003;290(6):754; author reply 755.
2003: Teunissen C E; Dijkstra C D; Polman C H; Hoogervorst E L J; von Bergmann K; Lütjohann D
Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients.
Neuroscience letters 2003;347(3):159-62.
2003: 't Hart Bert A; Vogels Jack T W E; Spijksma Gerwin; Brok Herbert P M; Polman Chris; van der Greef Jan
1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease.
Journal of the neurological sciences 2003;212(1-2):21-30.
2003: Geurts J J G; Wolswijk G; Bö L; van der Valk P; Polman C H; Troost D; Aronica E
Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis.
Brain : a journal of neurology 2003;126(Pt 8):1755-66.
2003: van Veen Tineke; Crusius J Bart A; van Winsen Lisa; Xia Bing; Barkhof Frederik; Salvador Peña A; Polman Chris H; Uitdehaag Bernard M J
CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis.
Journal of neuroimmunology 2003;140(1-2):188-93.
2003: Vogt Mario H J; Lopatinskaya Luba; Smits Monique; Polman Chris H; Nagelkerken Lex
Elevated osteopontin levels in active relapsing-remitting multiple sclerosis.
Annals of neurology 2003;53(6):819-22.
2003: Lopatinskaya Luba; van Boxel-Dezaire Anette H H; Barkhof Frederik; Polman Chris H; Lucas Cornelis J; Nagelkerken Lex
The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood.
Journal of neuroimmunology 2003;138(1-2):123-31.
2003: Polman Chris H; Uitdehaag Bernard N J; Klok Anne-Marie
Ocular comorbidity in multiple sclerosis.
Lancet 2003;361(9364):1230.
2003: Killestein J; Hoogervorst E L J; Reif M; Blauw B; Smits M; Uitdehaag B M J; Nagelkerken L; Polman C H
Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis.
Journal of neuroimmunology 2003;137(1-2):140-3.
2003: Hoogervorst E L J; Eikelenboom M J; Uitdehaag B M J; Polman C H
One year changes in disability in multiple sclerosis: neurological examination compared with patient self report.
Journal of neurology, neurosurgery, and psychiatry 2003;74(4):439-42.
2003: Lechner-Scott J; Kappos L; Hofman M; Polman C H; Ronner H; Montalban X; Tintore M; Frontoni M; Buttinelli C; Amato M P; Bartolozzi M L; Versavel M; Dahlke F; Kapp J-F; Gibberd R
Can the Expanded Disability Status Scale be assessed by telephone?
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(2):154-9.
2003: Inglese M; van Waesberghe J H T M; Rovaris M; Beckmann K; Barkhof F; Hahn D; Kappos L; Miller D H; Polman C; Pozzilli C; Thompson A J; Yousry T A; Wagner K; Comi G; Filippi M
The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.
Neurology 2003;60(5):853-60.
2003: Filippini Graziella; Munari Luca; Incorvaia Barbara; Ebers George C; Polman Chris; D'Amico Roberto; Rice George P A
Interferons in relapsing remitting multiple sclerosis: a systematic review.
Lancet 2003;361(9357):545-52.
2003: Eikelenboom M J; Petzold A; Lazeron R H C; Silber E; Sharief M; Thompson E J; Barkhof F; Giovannoni G; Polman C H; Uitdehaag B M J
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.
Neurology 2003;60(2):219-23.
2003: Polman C; Kappos L; White R; Dahlke F; Beckmann K; Pozzilli C; Thompson A; Petkau J; Miller D;
Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b.
Neurology 2003;60(1):37-43.
2003: Hoogervorst E L J; de Jonge P; Jelles B; Huyse F J; Heeres I; van der Ploeg H M; Uitdehaag B M J; Polman C H
The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment.
Journal of neurology, neurosurgery, and psychiatry 2003;74(1):20-4.
2002: Kalkers N F; Barkhof F; Bergers E; van Schijndel R; Polman C H
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(6):532-3.
2002: Bergers E; Bot J C J; De Groot C J A; Polman C H; Lycklama à Nijeholt G J; Castelijns J A; van der Valk P; Barkhof F
Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions.
Neurology 2002;59(11):1766-71.
2002: Eikelenboom M J; Killestein J; Izeboud T; Kalkers N F; van Lier R A W; Barkhof F; Uitdehaag B M J; Polman C H
Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis.
Journal of neuroimmunology 2002;133(1-2):225-32.
2002: Killestein J; Hintzen R Q; Uitdehaag B M J; Baars P A; Roos M T; van Lier R A W; Polman C H
Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta.
Journal of neuroimmunology 2002;133(1-2):217-24.
2002: Kalkers Nynke F; Ameziane Najim; Bot Joost C J; Minneboo Arjan; Polman Chris H; Barkhof Frederik
Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.
Archives of neurology 2002;59(10):1572-6.
2002: Hoogervorst E L J; Polman C H; Barkhof F
Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(5):415-9.
2002: Kalkers N F; Vrenken H; Uitdehaag B M J; Polman C H; Barkhof F
Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(5):410-4.
2002: Uitdehaag B M J; Adèr H J; Roosma T J A; de Groot V; Kalkers N F; Polman C H
Multiple sclerosis functional composite: impact of reference population and interpretation of changes.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(5):366-71.
2002: de Jong B A; Huizinga T W J; Zanelli E; Giphart M J; Bollen E L E M; Uitdehaag B M J; Polman C H; Westendorp R G J
Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region.
Neurology 2002;59(4):549-55.
2002: van Veen T; Kalkers N F; Crusius J B A; van Winsen L; Barkhof F; Jongen P J H; Peña A S; Polman C H; Uitdehaag B M J
The FAS-670 polymorphism influences susceptibility to multiple sclerosis.
Journal of neuroimmunology 2002;128(1-2):95-100.
2002: Petzold A; Eikelenboom M J; Gveric D; Keir G; Chapman M; Lazeron R H C; Cuzner M L; Polman C H; Uitdehaag B M J; Thompson E J; Giovannoni G
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.
Brain : a journal of neurology 2002;125(Pt 7):1462-73.
2002: Bergers Elisabeth; Bot Joost C J; van der Valk Paul; Castelijns Jonas A; Lycklama a Nijeholt Geert J; Kamphorst Wouter; Polman Chris H; Blezer Erwin L A; Nicolay Klaas; Ravid Rivka; Barkhof Frederik
Diffuse signal abnormalities in the spinal cord in multiple sclerosis: direct postmortem in situ magnetic resonance imaging correlated with in vitro high-resolution magnetic resonance imaging and histopathology.
Annals of neurology 2002;51(5):652-6.
2002: de Jong Brigit A; Huizinga Tom W J; Bollen Eduard L E M; Uitdehaag Bernard M J; Bosma Gerlof P Th; van Buchem Mark A; Remarque Edmond J; Burgmans Alexandra C S; Kalkers Nynke F; Polman Chris H; Westendorp Rudi G J
Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis.
Journal of neuroimmunology 2002;126(1-2):172-9.
2002: Killestein J; Hoogervorst E L J; Reif M; Kalkers N F; Van Loenen A C; Staats P G M; Gorter R W; Uitdehaag B M J; Polman C H
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Neurology 2002;58(9):1404-7.
2002: Ingle G T; Stevenson V L; Miller D H; Leary S M; Rovaris M; Barkhof F; Brochet B; Dousset V; Filippi M; Montalban X; Kalkers N F; Polman C H; Rovira A; Thompson A J
Two-year follow-up study of primary and transitional progressive multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(2):108-14.
2002: Killestein J; Rep M H G; Meilof J F; Adèr H J; Uitdehaag B M J; Barkhof F; van Lier R A W; Polman C H
Seasonal variation in immune measurements and MRI markers of disease activity in MS.
Neurology 2002;58(7):1077-80.
2002: Bot Joost C J; Barkhof Frederik; Lycklama à Nijeholt Geert; van Schaardenburg Dirkjan; Voskuyl Alexandre E; Ader Herman J; Pijnenburg Jolanda A L; Polman Chris H; Uitdehaag Bernard M J; Vermeulen Erik G J; Castelijns Jonas A
Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging.
Radiology 2002;223(1):46-56.
2002: Killestein Joep; Olsson Tomas; Wallström Erik; Svenningsson Anders; Khademi Mohsen; Blumhardt Lance D; Fagius Jan; Hillert Jan; Landtblom Anne-Marie; Edenius Charlotte; Arfors Leopold; Barkhof Frederik; Polman Chris H
Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial.
Annals of neurology 2002;51(4):467-74.
2002: Hoogervorst Erwin L J; Kalkers Nynke F; Uitdehaag Bernard M J; Polman Chris H
A study validating changes in the multiple sclerosis functional composite.
Archives of neurology 2002;59(1):113-6.
2002: De Sonneville L M J; Boringa J B; Reuling I E W; Lazeron R H C; Adèr H J; Polman C H
Information processing characteristics in subtypes of multiple sclerosis.
Neuropsychologia 2002;40(11):1751-65.
2001: Molyneux P D; Barker G J; Barkhof F; Beckmann K; Dahlke F; Filippi M; Ghazi M; Hahn D; MacManus D; Polman C; Pozzilli C; Kappos L; Thompson A J; Wagner K; Yousry T; Miller D H;
Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.
Neurology 2001;57(12):2191-7.
2001: Brex P A; Molyneux P D; Smiddy P; Barkhof F; Filippi M; Yousry T A; Hahn D; Rolland Y; Salonen O; Pozzilli C; Polman C H; Thompson A J; Kappos L; Miller D H;
The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS.
Neurology 2001;57(12):2185-90.
2001: Kappos L; Polman C; Pozzilli C; Thompson A; Beckmann K; Dahlke F;
Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.
Neurology 2001;57(11):1969-75.
2001: Freeman J A; Thompson A J; Fitzpatrick R; Hutchinson M; Miltenburger C; Beckmann K; Dahlke F; Kappos L; Polman C; Pozzilli C;
Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.
Neurology 2001;57(10):1870-5.
2001: van Boxel-Dezaire A H; Smits M; van Trigt-Hoff S C; Killestein J; van Houwelingen J C; Polman C H; Nagelkerken L
Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis.
Journal of neuroimmunology 2001;120(1-2):152-60.
2001: Hoogervorst E L; Kalkers N F; van Winsen LML; Uitdehaag B M; Polman C H
Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(5):335-9.
2001: Kalkers N F; Bergers E; Castelijns J A; van Walderveen M A; Bot J C; Adèr H J; Polman C H; Barkhof F
Optimizing the association between disability and biological markers in MS.
Neurology 2001;57(7):1253-8.
2001: Killestein J; Kalkers N F; Meilof J F; Barkhof F; van Lier R A; Polman C H
TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS.
Neurology 2001;57(6):1129-31.
2001: van der Bruggen M A; Huisman H B; Beckerman H; Bertelsmann F W; Polman C H; Lankhorst G J
Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury.
Journal of neurology 2001;248(8):665-71.
2001: Boringa J B; Lazeron R H; Reuling I E; Adèr H J; Pfennings L; Lindeboom J; de Sonneville L M; Kalkers N F; Polman C H
The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(4):263-7.
2001: van Veen T; Crusius J B; Schrijver H M; Bouma G; Killestein J; van Winsen L; Salvador Peña A; Polman C H; Uitdehaag B M
Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis.
Annals of neurology 2001;50(2):275.
2001: Killestein J; Rep M H; Barkhof F; Roos M T; Adèr H J; van Lier R A; Polman C H
Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells.
Journal of neuroimmunology 2001;118(2):286-94.
2001: De Groot C J; Bergers E; Kamphorst W; Ravid R; Polman C H; Barkhof F; van der Valk P
Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions.
Brain : a journal of neurology 2001;124(Pt 8):1635-45.
2001: McDonald W I; Compston A; Edan G; Goodkin D; Hartung H P; Lublin F D; McFarland H F; Paty D W; Polman C H; Reingold S C; Sandberg-Wollheim M; Sibley W; Thompson A; van den Noort S; Weinshenker B Y; Wolinsky J S
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
Annals of neurology 2001;50(1):121-7.
2001: Barkhof F; van Waesberghe J H; Filippi M; Yousry T; Miller D H; Hahn D; Thompson A J; Kappos L; Brex P; Pozzilli C; Polman C H;
T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
Brain : a journal of neurology 2001;124(Pt 7):1396-402.
2001: Killestein J; Den Drijver B F; Van der Graaff W L; Uitdehaag B M; Polman C H; Van Lier R A
Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(3):145-50.
2001: Hoogervorst E L; van Winsen L M; Eikelenboom M J; Kalkers N F; Uitdehaag B M; Polman C H
Comparisons of patient self-report, neurologic examination, and functional impairment in MS.
Neurology 2001;56(7):934-7.
2001: Uitdehaag B M; Hoekstra K; Koper J W; Polman C H; Dijkstra C D
IFN-beta1b augments glucocorticoid-induced suppression of tumor necrosis factor-alpha production by increasing the number of glucocorticoid receptors on a human monocytic cell line.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2001;21(3):133-5.
2001: Morré S A; van Beek J; De Groot C J; Killestein J; Meijer C J; Polman C H; van der Valk P; Middeldorp J M; van Den Brule A J
Is Epstein-Barr virus present in the CNS of patients with MS?
Neurology 2001;56(5):692.
2001: Kalkers N F; Hintzen R Q; van Waesberghe J H; Lazeron R H; van Schijndel R A; Adèr H J; Polman C H; Barkhof F
Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy.
Journal of the neurological sciences 2001;184(2):155-62.
2001: van Walderveen M A; Lycklama A Nijeholt G J; Adèr H J; Jongen P J; Polman C H; Castelijns J A; Barkhof F
Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
Archives of neurology 2001;58(1):76-81.
2001: Kalkers N F; Bergers L; de Groot V; Lazeron R H; van Walderveen M A; Uitdehaag B M; Polman C H; Barkhof F
Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.
Neurology 2001;56(2):215-9.
2001: Nijeholt G J; Bergers E; Kamphorst W; Bot J; Nicolay K; Castelijns J A; van Waesberghe J H; Ravid R; Polman C H; Barkhof F
Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype.
Brain : a journal of neurology 2001;124(Pt 1):154-66.
2001: Rice G P; Incorvaia B; Munari L; Ebers G; Polman C; D'Amico R; Filippini G
Interferon in relapsing-remitting multiple sclerosis.
Cochrane database of systematic reviews (Online) 2001;(4):CD002002.
2000: Molyneux P D; Kappos L; Polman C; Pozzilli C; Barkhof F; Filippi M; Yousry T; Hahn D; Wagner K; Ghazi M; Beckmann K; Dahlke F; Losseff N; Barker G J; Thompson A J; Miller D H
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
Brain : a journal of neurology 2000;123 ( Pt 11)():2256-63.
2000: Arnoldus J H; Killestein J; Pfennings L E; Jelles B; Uitdehaag B M; Polman C H
Quality of life during the first 6 months of interferon-beta treatment in patients with MS.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(5):338-42.
2000: de Jong B A; Schrijver H M; Huizinga T W; Bollen E L; Polman C H; Uitdehaag B M; Kersbergen M C; Sturk A; Westendorp R G
Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis.
Annals of neurology 2000;48(4):641-6.
2000: van Boxel-Dezaire A H; van Trigt-Hoff S C; Killestein J; Schrijver H M; van Houwelingen J C; Polman C H; Nagelkerken L
Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
Annals of neurology 2000;48(3):313-22.
2000: Lazeron R H; Langdon D W; Filippi M; van Waesberghe J H; Stevenson V L; Boringa J B; Origgi D; Thompson A J; Falautano M; Polman C H; Barkhof F
Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(4):280-5.
2000: Thompson A J; Montalban X; Barkhof F; Brochet B; Filippi M; Miller D H; Polman C H; Stevenson V L; McDonald W I
Diagnostic criteria for primary progressive multiple sclerosis: a position paper.
Annals of neurology 2000;47(6):831-5.
2000: Stevenson V L; Miller D H; Leary S M; Rovaris M; Barkhof F; Brochet B; Dousset V; Filippi M; Hintzen R; Montalban X; Polman C H; Rovira A; de Sa J; Thompson A J
One year follow up study of primary and transitional progressive multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2000;68(6):713-8.
2000: Lycklama à Nijeholt G J; Castelijns J A; Lazeron R H; van Waesberghe J H; Polman C H; Uitdehaag B M; Barkhof F
Magnetization transfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disability.
Journal of neuroimaging : official journal of the American Society of Neuroimaging 2000;10(2):67-72.
2000: Tan I L; Lycklama à Nijeholt G J; Polman C H; Adèr H J; Barkhof F
Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(2):99-104.
2000: Kalkers N F; de Groot V; Lazeron R H; Killestein J; Adèr H J; Barkhof F; Lankhorst G J; Polman C H
MS functional composite: relation to disease phenotype and disability strata.
Neurology 2000;54(6):1233-9.
2000: Killestein J; Schrijver H M; Crusius J B; Pérez C; Uitdehaag B M; Peña A S; Polman C H
Intracellular adhesion molecule-1 polymorphisms and genetic susceptibility to multiple sclerosis: additional data and meta-analysis.
Annals of neurology 2000;47(2):277-9.
2000: Bot J C; Barkhof F; Lycklama à Nijeholt G J; Bergers E; Polman C H; Adèr H J; Castelijns J A
Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis.
European radiology 2000;10(5):753-8.
2000: Lycklama à Nijeholt G J; Uitdehaag B M; Bergers E; Castelijns J A; Polman C H; Barkhof F
Spinal cord magnetic resonance imaging in suspected multiple sclerosis.
European radiology 2000;10(2):368-76.
1999: van Waesberghe J H; Kamphorst W; De Groot C J; van Walderveen M A; Castelijns J A; Ravid R; Lycklama à Nijeholt G J; van der Valk P; Polman C H; Thompson A J; Barkhof F
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability.
Annals of neurology 1999;46(5):747-54.
1999: Pfennings L E; van der Ploeg H M; Cohen L; Polman C H
A comparison of responsiveness indices in multiple sclerosis patients.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1999;8(6):481-9.
1999: Pfennings L E; Van der Ploeg H M; Cohen L; Bramsen I; Polman C H; Lankhorst G J; Vleugels L
A health-related quality of life questionnaire for multiple sclerosis patients.
Acta neurologica Scandinavica 1999;100(3):148-55.
1999: Pfennings L; Cohen L; Miller D; Gerbaud L; Vleugels L; Freeman J; Vernay D; Biolay S; Ketelaer P; Thompson A; Polman C; van der Ploeg H
Using the Short Form-36 with multiple sclerosis patients in five countries: a cross-cultural comparison.
Psychological reports 1999;85(1):19-31.
1999: Pfennings L; Cohen L; Adèr H; Polman C; Lankhorst G; Smits R; van der Ploeg H
Exploring differences between subgroups of multiple sclerosis patients in health-related quality of life.
Journal of neurology 1999;246(7):587-91.
1999: van Walderveen M A; Barkhof F; Pouwels P J; van Schijndel R A; Polman C H; Castelijns J A
Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy.
Annals of neurology 1999;46(1):79-87.
1999: Camp S J; Stevenson V L; Thompson A J; Miller D H; Borras C; Auriacombe S; Brochet B; Falautano M; Filippi M; Hérissé-Dulo L; Montalban X; Parrcira E; Polman C H; De Sa J; Langdon D W
Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates.
Brain : a journal of neurology 1999;122 ( Pt 7)():1341-8.
1999: van Boxel-Dezaire A H; Hoff S C; van Oosten B W; Verweij C L; Dräger A M; Adèr H J; van Houwelingen J C; Barkhof F; Polman C H; Nagelkerken L
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis.
Annals of neurology 1999;45(6):695-703.
1999: Rep M H; Schrijver H M; van Lopik T; Hintzen R Q; Roos M T; Adèr H J; Polman C H; van Lier R A
Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients.
Journal of neuroimmunology 1999;96(1):92-100.
1999: van Walderveen M A; Truyen L; van Oosten B W; Castelijns J A; Lycklama à Nijeholt G J; van Waesberghe J H; Polman C; Barkhof F
Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity.
Archives of neurology 1999;56(3):345-51.
1999: Stevenson V L; Miller D H; Rovaris M; Barkhof F; Brochet B; Dousset V; Dousset V; Filippi M; Montalban X; Polman C H; Rovira A; de Sa J; Thompson A J
Primary and transitional progressive MS: a clinical and MRI cross-sectional study.
Neurology 1999;52(4):839-45.
1999: Schrijver H M; Crusius J B; Uitdehaag B M; García González M A; Kostense P J; Polman C H; Peña A S
Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS.
Neurology 1999;52(3):595-9.
1999: Nasseri K; Uitdehaag B M; van Walderveen M A; Ader H J; Polman C H
Cardiovascular autonomic function in patients with relapsing remitting multiple sclerosis: a new surrogate marker of disease evolution?
European journal of neurology : the official journal of the European Federation of Neurological Societies 1999;6(1):29-33.
1999: Cohen L; Pouwer F; Pfennings L E; Lankhorst G J; van der Ploeg H M; Polman C H; Adèr H J; Jønnson A; Vleugels L
Factor structure of the Disability and Impact Profile in patients with multiple sclerosis.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1999;8(1-2):141-50.
1998: van Waesberghe J H; van Buchem M A; Filippi M; Castelijns J A; Rocca M A; van der Boom R; Polman C H; Barkhof F
MR outcome parameters in multiple sclerosis: comparison of surface-based thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a preliminary note).
AJNR. American journal of neuroradiology 1998;19(10):1857-62.
1998: van Oosten B W; Truyen L; Barkhof F; Polman C H
Choosing drug therapy for multiple sclerosis. An update.
Drugs 1998;56(4):555-69.
1998: Pfennings L; Cohen L; van der Ploeg H; Polman C; Lankhorst G
Reliability of two measures of health-related quality of life in patients with multiple sclerosis.
Perceptual and motor skills 1998;87(1):111-4.
1998: van Walderveen M A; Barkhof F; Tas M W; Polman C; Frequin S T; Hommes O R; Thompson A J; Valk J
Patterns of brain magnetic resonance abnormalities on T2-weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross-sectional study.
European neurology 1998;40(2):91-8.
1998: van Oosten B W; Barkhof F; Scholten P E; von Blomberg B M; Adèr H J; Polman C H
Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.
Archives of neurology 1998;55(6):793-8.
1998: van Walderveen M A; Kamphorst W; Scheltens P; van Waesberghe J H; Ravid R; Valk J; Polman C H; Barkhof F
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.
Neurology 1998;50(5):1282-8.
1998: Nijeholt G J; van Walderveen M A; Castelijns J A; van Waesberghe J H; Polman C; Scheltens P; Rosier P F; Jongen P J; Barkhof F
Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms.
Brain : a journal of neurology 1998;121 ( Pt 4)():687-97.
1998: van Waesberghe J H; van Walderveen M A; Castelijns J A; Scheltens P; Lycklama à Nijeholt G J; Polman C H; Barkhof F
Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR.
AJNR. American journal of neuroradiology 1998;19(4):675-83.
1998: Barkhof F J; Elton M; Lindeboom J; Tas M W; Schmidt W F; Hommes O R; Polman C H; Kok A; Valk J
Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study.
Journal of neurology 1998;245(3):153-8.
1998: Nasseri K; TenVoorde B J; Adèr H J; Uitdehaag B M; Polman C H
Longitudinal follow-up of cardiovascular reflex tests in multiple sclerosis.
Journal of the neurological sciences 1998;155(1):50-4.
1998: Lycklama à Nijeholt G J; Castelijns J A; Weerts J; Adèr H; van Waesberghe J H; Polman C; Barkhof F
Sagittal MR of multiple sclerosis in the spinal cord: fast versus conventional spin-echo imaging.
AJNR. American journal of neuroradiology 1998;19(2):355-60.
1997: Barkhof F; van Waesberghe J H; Uitdehaag B M; Polman C H
Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images.
Annals of neurology 1997;42(6):982.
1997: Barkhof F; Filippi M; Miller D H; Scheltens P; Campi A; Polman C H; Comi G; Adèr H J; Losseff N; Valk J
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Brain : a journal of neurology 1997;120 ( Pt 11)():2059-69.
1997: van Waesberghe J H; Castelijns J A; Roser W; Silver N; Yousry T; Lycklama à Nijeholt G J; Adèr H J; Uitdehaag B M; Radue E W; Polman C H; Kappos L; Miller D H; Barkhof F
Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions.
AJNR. American journal of neuroradiology 1997;18(7):1279-85.
1997: van Oosten B W; Uitdehaag B M; Barkhof F; Hartung H P; Wagstaff J; Polman C H
Interleukin-2 therapy does not exacerbate multiple sclerosis.
Neurology 1997;49(2):633-4.
1997: van Oosten B W; Lai M; Hodgkinson S; Barkhof F; Miller D H; Moseley I F; Thompson A J; Rudge P; McDougall A; McLeod J G; Adèr H J; Polman C H
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.
Neurology 1997;49(2):351-7.
1997: Thompson A J; Polman C H; Miller D H; McDonald W I; Brochet B; Filippi M Montalban X; De Sá J
Primary progressive multiple sclerosis.
Brain : a journal of neurology 1997;120 ( Pt 6)():1085-96.
1997: Lycklama à Nijeholt G J; Barkhof F; Scheltens P; Castelijns J A; Adèr H; van Waesberghe J H; Polman C; Jongen S J; Valk J
MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability.
AJNR. American journal of neuroradiology 1997;18(6):1041-8.
1997: Rep M H; van Oosten B W; Roos M T; Adèr H J; Polman C H; van Lier R A
Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.
The Journal of clinical investigation 1997;99(9):2225-31.
1997: Barkhof F; Polman C
Oral or intravenous methylprednisolone for acute relapses of MS?
Lancet 1997;349(9056):893-4.
1997: Huizinga T W; Westendorp R G; Bollen E L; Keijsers V; Brinkman B M; Langermans J A; Breedveld F C; Verweij C L; van de Gaer L; Dams L; Crusius J B; García-Gonzalez A; van Oosten B W; Polman C H; Peña A S
TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients.
Journal of neuroimmunology 1997;72(2):149-53.
1997: Truyen L; Barkhof F; Tas M; Van Walderveen M A; Frequin S T; Hommes O R; Nauta J J; Polman C H; Valk J
Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials.
Multiple sclerosis (Houndmills, Basingstoke, England) 1997;2(6):283-90.
1997: van Waesberghe J H; Castelijns J A; Scheltens P; Truyen L; Lycklana A Nijeholt G J; Hoogenraad F G; Polman C H; Valk J; Barkhof F
Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions.
Magnetic resonance imaging 1997;15(2):155-62.
1996: van Oosten B W; Barkhof F; Truyen L; Boringa J B; Bertelsmann F W; von Blomberg B M; Woody J N; Hartung H P; Polman C H
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.
Neurology 1996;47(6):1531-4.
1996: Truyen L; van Waesberghe J H; van Walderveen M A; van Oosten B W; Polman C H; Hommes O R; Adèr H J; Barkhof F
Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.
Neurology 1996;47(6):1469-76.
1996: van Oosten B W; Lai M; Barkhof F; Miller D H; Moseley I F; Thompson A J; Hodgkinson S; Polman C H
A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 1996;1(6):339-42.
1996: Rep M H; Hintzen R Q; Polman C H; van Lier R A
Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells.
Journal of neuroimmunology 1996;67(2):111-8.
1996: Lankhorst G J; Jelles F; Smits R C; Polman C H; Kuik D J; Pfennings L E; Cohen L; van der Ploeg H M; Ketelaer P; Vleugels L
Quality of life in multiple sclerosis: the disability and impact profile (DIP).
Journal of neurology 1996;243(6):469-74.
1996: van Oosten B W; Rep M H; van Lier R A; Scholten P E; von Blomberg B M; Pflughaupt K W; Hartung H P; Adèr H J; Polman C H
A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis.
Journal of neuroimmunology 1996;66(1-2):49-55.
1996: Truyen L; Barkhof F; Frequin S T; Polman C H; Tobi H; Hommes O R; Valk J
Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine.
Multiple sclerosis (Houndmills, Basingstoke, England) 1996;1(4):213-7.
1996: Uitdehaag B M; Polman C H; Sontrop K; Dijkstra C D
The effect of the 21-aminosteroid U74006F on the clinical course of acute experimental allergic encephalomyelitis.
Journal of the neurological sciences 1996;135(1):18-20.
1996: van Waesberghe J H; Castelijns J A; Weerts J G; Nijeholt G J; Hillegers J P; Polman C H; Barkhof F
Disappearance of multiple sclerosis lesions with severely prolonged T1 on images obtained by a FLAIR pulse sequence.
Magnetic resonance imaging 1996;14(2):209-13.
1995: van Walderveen M A; Barkhof F; Hommes O R; Polman C H; Tobi H; Frequin S T; Valk J
Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images.
Neurology 1995;45(9):1684-90.
1995: van Oosten B W; Truyen L; Barkhof F; Polman C H
Multiple sclerosis therapy. A practical guide.
Drugs 1995;49(2):200-12.
1995: Tas M W; Barkhol F; van Walderveen M A; Polman C H; Hommes O R; Valk J
The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis.
AJNR. American journal of neuroradiology 1995;16(2):259-64.
1995: Hintzen R Q; Fiszer U; Fredrikson S; Rep M; Polman C H; van Lier R A; Link H
Analysis of CD27 surface expression on T cell subsets in MS patients and control individuals.
Journal of neuroimmunology 1995;56(1):99-105.
1995: Polman C H; Dahlke F; Thompson A J; Ghazi M; Kappos L; Miltenburger C; Pozilli C
Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.
Multiple sclerosis (Houndmills, Basingstoke, England) 1995;1 Suppl 1():S51-4.
1994: Polman C H; Bertelsmann F W; de Waal R; van Diemen H A; Uitdehaag B M; van Loenen A C; Koetsier J C
4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
Archives of neurology 1994;51(11):1136-9.
1994: Uitdehaag B M; Polman C H; de Groot C J; Dijkstra C D
Effect of K+ channel blockers on the clinical course and histological features of experimental allergic encephalomyelitis.
Acta neurologica Scandinavica 1994;90(4):299-301.
1994: Smits R C; Emmen H H; Bertelsmann F W; Kulig B M; van Loenen A C; Polman C H
The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.
Neurology 1994;44(9):1701-5.
1994: Rep M H; Hintzen R Q; Polman C H; van Lier R A
Functional defects in peripheral blood T cells of multiple sclerosis patients. Diminished in vitro responsiveness in accessory cell dependent activation systems.
Journal of neuroimmunology 1994;52(2):139-46.
1994: Polman C H; Bertelsmann F W; van Loenen A C; Koetsier J C
4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety.
Archives of neurology 1994;51(3):292-6.
1994: van Walderveen M A; Tas M W; Barkhof F; Polman C H; Frequin S T; Hommes O R; Valk J
Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis.
Neurology 1994;44(2):327-9.
1994: Dijkstra C D; van der Voort E R; De Groot C J; Huitinga I; Uitdehaag B M; Polman C H; Berkenbosch F
Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis.
Psychoneuroendocrinology 1994;19(2):135-42.
1993: Taphoorn M J; van Someren E; Snoek F J; Strijers R L; Swaab D F; Visscher F; de Waal L P; Polman C H
Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis.
Journal of neurology 1993;240(7):446-8.
1993: Van Diemen H A; Polman C H; Koetsier J C; Van Loenen A C; Nauta J J; Bertelsmann F W
4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety.
Clinical neuropharmacology 1993;16(3):195-204.
1993: Uitdehaag B M; de Groot C J; Kreike A; van der Meide P H; Polman C H; Dijkstra C D
The significance of in-situ Ia antigen expression in the pathogenesis of autoimmune central nervous system disease.
Journal of autoimmunity 1993;6(3):323-35.
1993: van Diemen H A; Polman C H; van Dongen M M; Nauta J J; Strijers R L; van Loenen A C; Bertelsmann F W; Koetsier J C
4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study.
Journal of the neurological sciences 1993;116(2):220-6.
1993: Dijkstra C D; Polman C H; Berkenbosch F
Multiple sclerosis: some possible therapeutic opportunities.
Trends in pharmacological sciences 1993;14(4):124-9.
1992: van Diemen H A; Polman C H; van Dongen T M; van Loenen A C; Nauta J J; Taphoorn M J; van Walbeek H K; Koetsier J C
The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
Annals of neurology 1992;32(2):123-30.
1992: Hintzen R Q; Polman C H; Lucas C J; van Lier R A
Multiple sclerosis: immunological findings and possible implications for therapy.
Journal of neuroimmunology 1992;39(1-2):1-10.
1992: Dijkstra C D; van der Voort E R; De Groot C J; Uitdehaag B M; Polman C H; Berkenbosch F
The therapeutic effect of bromocriptine on acute and chronic experimental allergic encephalomyelitis.
Annals of neurology 1992;31(4):450-1.
1992: Van Diemen H A; Van Dongen M M; Nauta J J; Lanting P; Polman C H
Pupillary light reflex latency in patients with multiple sclerosis.
Electroencephalography and clinical neurophysiology 1992;82(3):213-9.
1992: van der Horst A; de Goede P N; van Diemen H A; Polman C H; Martens H J
Determination of 4-aminopyridine in serum by solid-phase extraction and high-performance liquid chromatography.
Journal of chromatography 1992;574(1):166-9.
1992: van Diemen H A; Lanting P; Koetsier J C; Strijers R L; van Walbeek H K; Polman C H
Evaluation of the visual system in multiple sclerosis: a comparative study of diagnostic tests.
Clinical neurology and neurosurgery 1992;94(3):191-5.
1992: van Diemen H A; van Dongen M M; Dammers J W; Polman C H
Increased visual impairment after exercise (Uhthoff's phenomenon) in multiple sclerosis: therapeutic possibilities.
European neurology 1992;32(4):231-4.
1991: Hintzen R Q; van Lier R A; Kuijpers K C; Baars P A; Schaasberg W; Lucas C J; Polman C H
Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients.
Journal of neuroimmunology 1991;35(1-3):211-7.
1991: Anema J R; Heijenbrok M W; Faes T J; Heimans J J; Lanting P; Polman C H
Cardiovascular autonomic function in multiple sclerosis.
Journal of the neurological sciences 1991;104(2):129-34.
1991: Uitdehaag B M; Polman C H; de Groot C J; Huitinga I; Dijkstra C D
Failure of sulfasalazine to influence experimental autoimmune encephalomyelitis.
Acta neurologica Scandinavica 1991;84(2):173-4.
1991: van Dongen M M; Bertelsmann F W; Polman C H
Sensitivity of eye movement registration and visual evoked potentials in evaluation of therapy in patients with multiple sclerosis.
Journal of the neurological sciences 1991;102(1):25-31.
1991: Barkhof F; Scheltens P; Valk J; Waalewijn C; Uitdehaag B M; Polman C H
Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium- "enhanced" STIR imaging.
Neuroradiology 1991;33(1):70-1.
1990: Polman C H; van Diemen H A; van Dongen M M; Koetsier J C; van Loenen A C; van Walbeek H K
4-Aminopyridine in multiple sclerosis.
Annals of neurology 1990;28(4):589.
1990: Heimans J J; De Visser M; Polman C H; Nauta J; Kamphorst W; Troost D
Accuracy and interobserver variation in the interpretation of computed tomography in solitary brain lesions.
Archives of neurology 1990;47(5):520-3.
1989: Uitdehaag B M; Polman C H; Valk J; Koetsier J C; Lucas C J
Magnetic resonance imaging studies in multiple sclerosis twins.
Journal of neurology, neurosurgery, and psychiatry 1989;52(12):1417-9.
1989: Matthaei I; Polman C H; de Groot C J; Dijkstra C D; Koetsier J C; Sminia T
Observer agreement in the assessment of clinical signs in experimental allergic encephalomyelitis.
Journal of neuroimmunology 1989;23(1):25-8.
1988: Polman C H; Matthaei I; de Groot C J; Koetsier J C; Sminia T; Dijkstra C D
Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat.
Journal of neuroimmunology 1988;17(3):209-16.
1988: Dijkstra C D; De Groot C J; Koetsier J C; Matthaei I; Polman C H; Sminia T
Low-dose cyclosporin A induces relapsing experimental allergic encephalomyelitis in the Lewis rat.
Annals of the New York Academy of Sciences 1988;540():549-50.
1988: Breukelman A J; Polman C H; de Slegte R G; Koetsier J C
Neuromyelitis optica (Devic's syndrome): not always multiple sclerosis.
Clinical neurology and neurosurgery 1988;90(4):357-60.
1987: Polman C H; de Groot C J; Koetsier J C; Sminia T; Veerman A J
Cerebrospinal fluid cells in multiple sclerosis and other neurological diseases: an immunocytochemical study.
Journal of neurology 1987;234(1):19-22.
1987: Polman C H; Dijkstra C D; de Groot C J; Koetsier J C; Sminia T
Presence of Ia-positive cells in the central nervous system of the rat during various pathological conditions.
International archives of allergy and applied immunology 1987;83(1):109-11.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Chris Polman

Research Profile (preview)

Disorders

Concepts & Ideas

Anatomy

Physiology

Chemicals & Drugs

Procedures

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Chris Polman (preview)

All Publications